Eden Biodesign and Borean Pharma ApS sign deal to develop novel therapeutic candidate for the treatment of cancer
MBP-DC-SIGN is one of Borean's products to be based on the Mannose-Binding protein (MBP) platform. The MBP platform is delivering a series of highly potent therapeutics for the treatment of cancers, and is the only scaffold that can induce complement-induced lysis.
The agreement with Borean Pharma is the fourth contract to be announced by Eden Biodesign in the past 7 weeks, following announcements for cGMP manufacturing and development projects with CRUK, University of Birmingham and UMIP.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.